{
    "hands_on_practices": [
        {
            "introduction": "A cornerstone of modern pharmacogenomic implementation is the translation of complex genetic information into a simple, quantitative metric that can guide clinical decisions. The activity score system, used by major consortia like CPIC and DPWG, provides this crucial link. This first practice problem will guide you through the construction and application of the fundamental algorithm used to calculate the cytochrome P450 2D6 ($CYP2D6$) activity score, turning a raw genotype into an actionable phenotype prediction .",
            "id": "4325426",
            "problem": "A clinical pharmacogenomics (PGx) implementation must translate cytochrome P450 family 2 subfamily D member 6 (CYP2D6) genotype calls into a quantitative activity score to harmonize prescribing recommendations across the Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG). Start from the following foundational bases:\n\n- The Central Dogma of Molecular Biology asserts that gene copy number influences the amount of protein produced, and thus the maximum catalytic rate of an enzyme.\n- The Michaelis–Menten relation $v = \\frac{V_{\\max}[S]}{K_{m} + [S]}$ indicates that, for a fixed substrate concentration $[S]$, the reaction velocity $v$ scales with $V_{\\max}$, which is proportional to the active enzyme concentration.\n- For diploid genes with possible copy-number variation, the total $V_{\\max}$ is the sum of per-allele contributions to active enzyme, assuming additive contributions to enzyme quantity from each allele.\n- CPIC and DPWG standardization uses three allele function classes: normal function, decreased function, and no function. Adopt the well-tested quantitative assignments consistent with the standardized CYP2D6 Activity Score framework: normal function contributes a normalized per-copy activity of $1$, decreased function contributes $0.5$, and no function contributes $0$.\n\nConstruct, from these bases, an algorithm that maps a CYP2D6 genotype $g$ to a dimensionless activity score $A(g)$ by aggregating per-allele contributions with appropriate scaling by copy number. Then, apply your derived algorithm to compute $A(g)$ for the following genotypes, using the conventional allele function classifications: $*$1 is normal function, $*$4 is no function, $*$5 (gene deletion) is no function, $*$10 is decreased function, and $*$41 is decreased function. Assume the notation $*4\\text{x}2$ indicates two copies of the $*$4 allele on one haplotype. The three genotypes are:\n- $*$1/$*$4,\n- $*4\\text{x}2$/$*10$,\n- $*$5/$*$41.\n\nExpress your three computed activity scores as dimensionless values. No rounding is required. Provide your final answer as a single row matrix containing the three values in the order listed above.",
            "solution": "The problem requires the construction of an algorithm to calculate the cytochrome P450 family 2 subfamily D member 6 (CYP2D6) activity score, $A(g)$, from a given genotype, $g$. This construction must be based on the provided foundational principles. Subsequently, this algorithm is to be applied to three specific genotypes.\n\nFirst, let us formalize the algorithm from the provided premises.\nThe problem states that for diploid genes, the total maximum reaction velocity, $V_{\\max}$, is the sum of per-allele contributions. The Michaelis-Menten relation, $v = \\frac{V_{\\max}[S]}{K_{m} + [S]}$, indicates that for a fixed substrate concentration $[S]$, the reaction velocity $v$ is directly proportional to $V_{\\max}$. The activity score is a quantitative measure of this enzymatic activity. Therefore, the total activity score for a given genotype must be the sum of the activity contributions from its constituent alleles.\n\nA genotype $g$ is composed of two haplotypes (one inherited from each parent), which we can denote as $h_1$ and $h_2$. The problem states that the total activity is an aggregation of per-allele contributions with scaling by copy number. This implies an additive model. Thus, the total activity score for genotype $g = h_1 / h_2$ is:\n$$A(g) = A(h_1) + A(h_2)$$\nwhere $A(h_1)$ and $A(h_2)$ are the activity scores of the individual haplotypes.\n\nThe activity score of a haplotype depends on the specific allele it contains and its copy number. Let $S(a)$ be the normalized per-copy activity value for an allele $a$. The problem provides the standardized quantitative assignments:\n- For a normal function allele, $S(a) = 1$.\n- For a decreased function allele, $S(a) = 0.5$.\n- For a no function allele, $S(a) = 0$.\n\nA haplotype may contain multiple copies of an allele, a phenomenon known as copy-number variation (CNV). If a haplotype $h$ consists of $n$ copies of an allele $a$ (denoted as $a\\text{x}n$), its contribution to the total activity score is the product of the copy number and the per-copy activity value:\n$$A(h) = n \\times S(a)$$\nIf a copy number is not explicitly specified for an allele on a haplotype, it is assumed to be $1$.\n\nCombining these, the general algorithm for calculating the activity score for a genotype $g$ composed of two haplotypes, $h_1 = a_1\\text{x}n_1$ and $h_2 = a_2\\text{x}n_2$, is:\n$$A(g) = (n_1 \\times S(a_1)) + (n_2 \\times S(a_2))$$\n\nNow, we apply this algorithm to the three specified genotypes using the provided allele function classifications:\n- $*1$: normal function, $S(*1) = 1$.\n- $*4$: no function, $S(*4) = 0$.\n- $*5$ (gene deletion): no function, $S(*5) = 0$.\n- $*10$: decreased function, $S(*10) = 0.5$.\n- $*41$: decreased function, $S(*41) = 0.5$.\n\nCase 1: Genotype $*1/*4$\n- Haplotype 1 is $*1$. This is one copy ($n_1 = 1$) of a normal function allele. Its contribution is $1 \\times S(*1) = 1 \\times 1 = 1$.\n- Haplotype 2 is $*4$. This is one copy ($n_2 = 1$) of a no function allele. Its contribution is $1 \\times S(*4) = 1 \\times 0 = 0$.\n- The total activity score is $A(*1/*4) = 1 + 0 = 1$.\n\nCase 2: Genotype $*4\\text{x}2/*10$\n- Haplotype 1 is $*4\\text{x}2$. This represents two copies ($n_1 = 2$) of the $*4$ allele, which is a no function allele. Its contribution is $2 \\times S(*4) = 2 \\times 0 = 0$.\n- Haplotype 2 is $*10$. This is one copy ($n_2 = 1$) of a decreased function allele. Its contribution is $1 \\times S(*10) = 1 \\times 0.5 = 0.5$.\n- The total activity score is $A(*4\\text{x}2/*10) = 0 + 0.5 = 0.5$.\n\nCase 3: Genotype $*5/*41$\n- Haplotype 1 is $*5$. This denotes a gene deletion, which is classified as one copy ($n_1=1$) of a no function allele. Its contribution is $1 \\times S(*5) = 1 \\times 0 = 0$.\n- Haplotype 2 is $*41$. This is one copy ($n_2 = 1$) of a decreased function allele. Its contribution is $1 \\times S(*41) = 1 \\times 0.5 = 0.5$.\n- The total activity score is $A(*5/*41) = 0 + 0.5 = 0.5$.\n\nThe calculated activity scores are dimensionless values, as required. The three scores, in the order requested, are $1$, $0.5$, and $0.5$.",
            "answer": "$$\n\\boxed{\n\\begin{pmatrix}\n1 & 0.5 & 0.5\n\\end{pmatrix}\n}\n$$"
        },
        {
            "introduction": "While a patient's genotype is static, their metabolic phenotype can be dynamic, influenced by concurrent medications that inhibit or induce enzyme activity. This phenomenon, known as phenoconversion, is a critical consideration in clinical pharmacogenomics. This exercise demonstrates how to quantify the impact of a strong drug inhibitor on a patient's baseline genetic capacity, effectively converting a normal metabolizer into a poor metabolizer and altering subsequent therapeutic recommendations .",
            "id": "4325418",
            "problem": "A clinical pharmacogenomics implementation scenario involves the cytochrome P450 2D6 (CYP2D6) enzyme regulated by genotype-derived activity score in the Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) frameworks. The CYP2D6 activity score is defined as the sum of the functional contributions of each allele, where a normal-function allele contributes $1$, a decreased-function allele contributes $0.5$, and a no-function allele contributes $0$. Consider a patient with genotype CYP2D6 $^{*}1/^{*}1$ taking paroxetine, a clinically recognized strong CYP2D6 inhibitor. For this problem, assume the inhibitor reduces the effective catalytic capacity of CYP2D6 by a fractional amount $I = 0.90$, and further assume that, within the clinically relevant range for phenotype assignment, the effective catalytic capacity relevant to activity score scales linearly with the fraction of active enzyme remaining.\n\nStarting from these definitions and assumptions, derive the effective activity score under inhibition from first principles and assign the functional phenotype category according to the following bins, consistent with widely used clinical interpretation ranges: poor metabolizer if $AS_{\\text{eff}}  0.25$, intermediate metabolizer if $0.25 \\leq AS_{\\text{eff}}  1.25$, normal metabolizer if $1.25 \\leq AS_{\\text{eff}} \\leq 2.25$, and ultrarapid metabolizer if $AS_{\\text{eff}} > 2.25$. Encode the phenotype category numerically as follows: poor metabolizer → $0$, intermediate metabolizer → $1$, normal metabolizer → $2$, ultrarapid metabolizer → $3$.\n\nCompute the effective activity score $AS_{\\text{eff}}$ for this CYP2D6 $^{*}1/^{*}1$ patient under paroxetine with $I = 0.90$ and determine the encoded phenotype category. Express your final answer as a row matrix with the first entry equal to $A S_{\\text{eff}}$ and the second entry equal to the numeric phenotype code. Round the effective activity score to $4$ significant figures.",
            "solution": "The solution proceeds in four steps:\n1.  Calculation of the baseline CYP2D6 activity score ($AS_{\\text{base}}$) from the patient's genotype.\n2.  Derivation of the effective activity score ($AS_{\\text{eff}}$) under inhibition.\n3.  Assignment of the functional phenotype based on the value of $AS_{\\text{eff}}$.\n4.  Encoding the assigned phenotype into the specified numerical value.\n\n**Step 1: Calculate the baseline activity score ($AS_{\\text{base}}$)**\n\nThe CYP2D6 activity score is defined as the sum of the numerical values assigned to the two alleles in a patient's genotype. The problem provides the following value assignments:\n- Normal-function allele: $1$\n- Decreased-function allele: $0.5$\n- No-function allele: $0$\n\nThe patient's genotype is given as CYP2D6 $^{*}1/^{*}1$. The $^{*}1$ allele is the reference allele for normal function. Therefore, each $^{*}1$ allele contributes a value of $1$ to the activity score.\n\nThe baseline activity score, $AS_{\\text{base}}$, is calculated as follows:\n$$\nAS_{\\text{base}} = (\\text{value of allele } ^{*}1) + (\\text{value of allele } ^{*}1) = 1 + 1 = 2\n$$\nWithout any external factors like inhibitors, this patient would be classified as a Normal Metabolizer, as their score of $2$ falls within the range $1.25 \\leq AS \\leq 2.25$.\n\n**Step 2: Derive the effective activity score ($AS_{\\text{eff}}$) under inhibition**\n\nThe patient is taking paroxetine, a strong CYP2D6 inhibitor. The inhibitor is stated to reduce the effective catalytic capacity of the enzyme by a fractional amount $I = 0.90$. This implies that the remaining fraction of active enzyme is $(1 - I)$.\n\nThe problem posits a crucial assumption: the effective activity score, $AS_{\\text{eff}}$, scales linearly with the fraction of active enzyme remaining. Based on this principle, the effective activity score can be calculated by multiplying the baseline activity score by the fraction of remaining enzyme activity.\n\nThe governing equation is:\n$$\nAS_{\\text{eff}} = AS_{\\text{base}} \\times (1 - I)\n$$\nSubstituting the known values for $AS_{\\text{base}}$ and $I$:\n$$\nAS_{\\text{base}} = 2\n$$\n$$\nI = 0.90\n$$\nThe calculation for $AS_{\\text{eff}}$ is:\n$$\nAS_{\\text{eff}} = 2 \\times (1 - 0.90) = 2 \\times 0.10 = 0.20\n$$\nThe problem requires the final value of $AS_{\\text{eff}}$ to be rounded to $4$ significant figures. Therefore:\n$$\nAS_{\\text{eff}} = 0.2000\n$$\n\n**Step 3: Assign the functional phenotype**\n\nThe functional phenotype is determined by comparing the calculated $AS_{\\text{eff}}$ to the specified activity score bins:\n- Poor metabolizer (PM): $AS_{\\text{eff}}  0.25$\n- Intermediate metabolizer (IM): $0.25 \\leq AS_{\\text{eff}}  1.25$\n- Normal metabolizer (NM): $1.25 \\leq AS_{\\text{eff}} \\leq 2.25$\n- Ultrarapid metabolizer (UM): $AS_{\\text{eff}} > 2.25$\n\nOur calculated value is $AS_{\\text{eff}} = 0.2000$. Comparing this to the bins:\n$$\n0.2000  0.25\n$$\nThis result places the patient in the poor metabolizer (PM) category. This phenomenon, where a drug interaction causes a patient's metabolic capacity to shift to a lower phenotype category, is known as phenoconversion.\n\n**Step 4: Encode the phenotype**\n\nThe problem provides a numerical encoding scheme for the phenotype categories:\n- Poor metabolizer → $0$\n- Intermediate metabolizer → $1$\n- Normal metabolizer → $2$\n- Ultrarapid metabolizer → $3$\n\nSince the patient is classified as a poor metabolizer, the corresponding numeric phenotype code is $0$.\n\nThe final answer is a row matrix containing the effective activity score ($AS_{\\text{eff}}$ rounded to $4$ significant figures) and the numeric phenotype code.\nThe first entry is $0.2000$.\nThe second entry is $0$.",
            "answer": "$$\n\\boxed{\\begin{pmatrix} 0.2000  0 \\end{pmatrix}}\n$$"
        },
        {
            "introduction": "The successful implementation of pharmacogenomic guidelines depends on the accuracy and reliability of laboratory testing, but real-world scenarios can present ambiguous or conflicting data. This advanced practice problem places you at the intersection of laboratory diagnostics and clinical decision-making in the face of uncertainty. You will use a risk-based framework, integrating Bayesian reasoning with principles of harm minimization, to navigate discordant $CYP2D6$ copy number results and formulate a safe and defensible clinical recommendation .",
            "id": "4325424",
            "problem": "A clinical laboratory is implementing workflows for cytochrome P450 2D6 (CYP2D6) copy number variation detection to support Clinical Pharmacogenetics Implementation Consortium (CPIC) and Dutch Pharmacogenetics Working Group (DPWG) guideline-based prescribing. A patient scheduled to receive codeine for postoperative analgesia has a single nucleotide polymorphism panel indicating a CYP2D6 haplotype consistent with two normal function alleles (for example, $\\ast 1/\\ast 1$). Copy number evaluation is performed by two orthogonal assays: Multiplex Ligation-dependent Probe Amplification (MLPA) and quantitative Polymerase Chain Reaction (qPCR). The MLPA assay indicates a duplication (that is, $\\geq 3$ total copies), while the qPCR assay indicates a normal total copy number of $2$. The laboratory’s validation data for the detection of duplications are as follows: MLPA sensitivity $0.95$, MLPA specificity $0.98$; qPCR sensitivity $0.85$, qPCR specificity $0.97$. The prevalence of CYP2D6 duplications in the local surgical population is estimated at $0.05$. Assume conditional independence of the two assays given the true copy state. \n\nYou are asked to construct a defensible decision framework for reporting and phenotype assignment that minimizes immediate patient risk for codeine therapy while acknowledging the uncertainty created by these discordant results, and that remains aligned with CPIC and DPWG principles for genotype-to-phenotype translation. Use a first-principles approach based on test characteristics (sensitivity, specificity), prior probability, and expected harm trade-offs. Let the relative harm of administering codeine to a true ultrarapid metabolizer (due to excessive morphine formation) be modeled as $H_{\\text{miss}} = 10$ arbitrary units if the patient is managed as a normal metabolizer, and the relative harm of unnecessarily avoiding codeine in a true normal metabolizer be $H_{\\text{over}} = 1$ arbitrary unit if the patient is managed as an ultrarapid metabolizer (for example, by recommending a non–CYP2D6-dependent alternative analgesic). \n\nWhich of the following decision frameworks best satisfies the requirements to minimize expected risk and transparently acknowledge uncertainty while maintaining consistency with CPIC and DPWG implementation standards?\n\nA. Report a definitive normal metabolizer phenotype and recommend standard codeine dosing because one assay indicates $2$ copies; note the discordance only in the internal laboratory record.\n\nB. Report a definitive ultrarapid metabolizer phenotype on the basis of the duplication call from MLPA; recommend avoiding codeine and tramadol; do not pursue additional testing given the lower expected harm.\n\nC. Report “indeterminate CYP2D6 copy number (discordant duplication result)” and defer definitive phenotype assignment; provide drug-specific, conservative recommendations for high-risk substrates (for example, avoid codeine and consider non–CYP2D6-dependent analgesics) pending resolution; initiate reflex orthogonal confirmation (for example, digital droplet PCR or long-read sequencing), and include a brief Bayesian risk summary in the report addendum.\n\nD. Average the two assay results to assign an intermediate metabolizer phenotype and recommend reduced codeine dosing; do not perform reflex testing because the average captures uncertainty.\n\nE. Defer reporting and clinical recommendations entirely until reflex testing is completed to eliminate uncertainty; provide no interim guidance on codeine use.",
            "solution": "The core of this problem is to determine the posterior probability of the patient having a true $CYP2D6$ duplication given the discordant test results, and then to use this probability to find the clinical management strategy that minimizes expected harm.\n\nLet's define the following events:\n- $D$: The patient has a true $CYP2D6$ duplication. The phenotype would be ultrarapid metabolizer (UM).\n- $D^c$: The patient does not have a duplication (i.e., has $2$ copies). The phenotype would be normal metabolizer (NM).\n- $M^+$: The MLPA assay is positive for a duplication.\n- $Q^-$: The qPCR assay is negative for a duplication.\n\nFrom the problem statement, we are given the following probabilities:\n- Prior probability of duplication: $P(D) = 0.05$.\n- Prior probability of no duplication: $P(D^c) = 1 - P(D) = 1 - 0.05 = 0.95$.\n- MLPA sensitivity: $\\text{Sens}_{\\text{MLPA}} = P(M^+|D) = 0.95$.\n- MLPA specificity: $\\text{Spec}_{\\text{MLPA}} = P(M^-|D^c) = 0.98$. From this, the false positive rate is $P(M^+|D^c) = 1 - \\text{Spec}_{\\text{MLPA}} = 1 - 0.98 = 0.02$.\n- qPCR sensitivity: $\\text{Sens}_{\\text{qPCR}} = P(Q^+|D) = 0.85$. From this, the false negative rate is $P(Q^-|D) = 1 - \\text{Sens}_{\\text{qPCR}} = 1 - 0.85 = 0.15$.\n- qPCR specificity: $\\text{Spec}_{\\text{qPCR}} = P(Q^-|D^c) = 0.97$.\n\nWe need to calculate the posterior probability of a duplication given the evidence, $P(D|M^+, Q^-)$, using Bayes' theorem:\n$$P(D|M^+, Q^-) = \\frac{P(M^+, Q^-|D)P(D)}{P(M^+, Q^-)}$$\nThe denominator, $P(M^+, Q^-)$, is the total probability of observing this specific pair of discordant results, which can be expanded using the law of total probability:\n$$P(M^+, Q^-) = P(M^+, Q^-|D)P(D) + P(M^+, Q^-|D^c)P(D^c)$$\nThe problem states that the assays are conditionally independent given the true disease state. Therefore:\n- $P(M^+, Q^-|D) = P(M^+|D) \\times P(Q^-|D) = 0.95 \\times 0.15 = 0.1425$\n- $P(M^+, Q^-|D^c) = P(M^+|D^c) \\times P(Q^-|D^c) = 0.02 \\times 0.97 = 0.0194$\n\nNow we can calculate the terms for Bayes' theorem:\n- Numerator: $P(M^+, Q^-|D)P(D) = 0.1425 \\times 0.05 = 0.007125$\n- Denominator: $P(M^+, Q^-) = (0.1425 \\times 0.05) + (0.0194 \\times 0.95) = 0.007125 + 0.01843 = 0.025555$\n\nThe posterior probability of the patient having a duplication is:\n$$P_{\\text{post}}(D) = P(D|M^+, Q^-) = \\frac{0.007125}{0.025555} \\approx 0.2788$$\nThe posterior probability of the patient not having a duplication is:\n$$P_{\\text{post}}(D^c) = 1 - P_{\\text{post}}(D) \\approx 1 - 0.2788 = 0.7212$$\n\nDespite the MLPA positive result, the posterior probability of a duplication is only about $28\\%$, making it more likely that the patient is a normal metabolizer. However, the decision must be based on minimizing expected harm.\n\nLet's evaluate the expected harm for the two possible management strategies:\n1.  **Manage as a Normal Metabolizer (NM):** Recommend standard codeine dosing. Harm occurs if this is incorrect (i.e., if the patient is actually a UM).\n    - Expected Harm $E[\\text{Harm}_{\\text{NM}}] = P_{\\text{post}}(D) \\times H_{\\text{miss}} + P_{\\text{post}}(D^c) \\times 0$\n    - $E[\\text{Harm}_{\\text{NM}}] = (0.2788 \\times 10) + (0.7212 \\times 0) = 2.788$ arbitrary units.\n\n2.  **Manage as an Ultrarapid Metabolizer (UM):** Recommend avoiding codeine. Harm occurs if this is incorrect (i.e., if the patient is actually an NM).\n    - Expected Harm $E[\\text{Harm}_{\\text{UM}}] = P_{\\text{post}}(D) \\times 0 + P_{\\text{post}}(D^c) \\times H_{\\text{over}}$\n    - $E[\\text{Harm}_{\\text{UM}}] = (0.2788 \\times 0) + (0.7212 \\times 1) = 0.7212$ arbitrary units.\n\nComparing the expected harms, $E[\\text{Harm}_{\\text{UM}}] = 0.7212$ is significantly lower than $E[\\text{Harm}_{\\text{NM}}] = 2.788$. Therefore, the risk-minimizing immediate action is to manage the patient as if they are an ultrarapid metabolizer, i.e., recommend avoiding codeine.\n\nNow we evaluate the options based on this analysis and general principles of clinical reporting (transparency, accuracy, safety).\n\nA. Report a definitive normal metabolizer phenotype and recommend standard codeine dosing because one assay indicates $2$ copies; note the discordance only in the internal laboratory record.\nThis corresponds to managing as an NM. Our calculation shows this is the higher-risk strategy. Furthermore, hiding the discordance from the clinical report is a serious breach of transparency and good laboratory practice.\nVerdict: Incorrect.\n\nB. Report a definitive ultrarapid metabolizer phenotype on the basis of the duplication call from MLPA; recommend avoiding codeine and tramadol; do not pursue additional testing given the lower expected harm.\nThe recommendation to avoid codeine is consistent with our risk-minimizing calculation. However, reporting a \"definitive\" UM phenotype is factually misleading, as the posterior probability is only $28\\%$. This creates a potentially permanent, and likely incorrect, entry in the patient's record. Best practice for discordant, clinically significant results is to pursue resolution, not to ignore the uncertainty.\nVerdict: Incorrect.\n\nC. Report “indeterminate CYP2D6 copy number (discordant duplication result)” and defer definitive phenotype assignment; provide drug-specific, conservative recommendations for high-risk substrates (for example, avoid codeine and consider non–CYP2D6-dependent analgesics) pending resolution; initiate reflex orthogonal confirmation (for example, digital droplet PCR or long-read sequencing), and include a brief Bayesian risk summary in the report addendum.\nThis option correctly addresses all facets of the problem.\n1.  It acknowledges uncertainty (\"indeterminate\").\n2.  It follows the risk-minimizing strategy for immediate patient care (\"avoid codeine\").\n3.  It follows best laboratory practice by seeking to resolve the discordance (\"initiate reflex orthogonal confirmation\").\n4.  It embodies maximal transparency by explaining the reasoning (\"Bayesian risk summary\").\nThis framework is fully consistent with the principles of CPIC and DPWG.\nVerdict: Correct.\n\nD. Average the two assay results to assign an intermediate metabolizer phenotype and recommend reduced codeine dosing; do not perform reflex testing because the average captures uncertainty.\nThis is scientifically nonsensical. One cannot \"average\" a positive and a negative categorical result. The resulting phenotype (intermediate metabolizer) is not a logical outcome of the possible genotypes (NM or UM). Recommending reduced codeine dosing for a potential UM is contraindicated by safety guidelines.\nVerdict: Incorrect.\n\nE. Defer reporting and clinical recommendations entirely until reflex testing is completed to eliminate uncertainty; provide no interim guidance on codeine use.\nThis approach creates a dangerous information vacuum. The patient is facing a near-term clinical decision (postoperative analgesia). Withholding safety-critical information, even if uncertain, fails the primary duty to minimize patient risk. A laboratory has an obligation to provide the best possible guidance with the information available.\nVerdict: Incorrect.",
            "answer": "$$\\boxed{C}$$"
        }
    ]
}